← Eichor
Study identifier: NCT06693440 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

The Immune Assessment of PD-1 Antibody Therapy in Tumor

Condition: Efficacy, Team · Adverse Event  ·  Sponsor: Quanli Gao

PhaseN/A
Planned participants3000
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This retrospective study will leverage previous immune function monitoring results in conjunction with clinical case data at this medical center.

This description comes directly from the study's public registry record.

Talk to the study team

Xiaomin Fu  ·  +86037165587483  ·  fuxiaomin0880@126.com

Xiaomin Fu  ·  +86037165587483  ·  zlyygql0855@zzu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer HospitalZhengzhou, Henan, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06693440